GSK/MMV win FDA 'breakthrough' status for malaria drug tafenoquine
This article was originally published in Scrip
Executive Summary
The US FDA has granted breakthrough therapy designation to GlaxoSmithKline's (GSK) and Medicines for Malaria Venture's (MMV) experimental drug tafenoquine as to treat and prevent relapse of Plasmodium vivax malaria, a neglected tropical disease, which is a major cause of uncomplicated malaria.
You may also be interested in...
Keeping Track: Flurry Of Approvals Rolls Over Into Holiday Season
The latest drug development news and highlights from our US FDA Performance Tracker.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.